Year : 2015  |  Volume : 17  |  Issue : 5  |  Page : 767-768

From bench to bedside: bipolar androgen therapy in a pilot clinical study

1 Department of Internal Medicine, Singapore General Hospital, Singapore
2 Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Correspondence Address:
Phillip J Gray
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1008-682X.151390

Rights and Permissions

Prostate cancer remains a leading cause of cancer death in Europe and the United States and is an emerging problem in Asia despite significant improvements in available treatments over the last few decades. Androgen deprivation therapy (ADT) has been the core treatment of advance-staged disease since the discovery of prostate cancer's androgen dependence in 1941 by Huggins et al. [1] Options for initial medical treatment include gonadotropin-releasing hormone analogues such as leuprolide (LHRH agonist) and degarelix (LHRH antagonist) and androgen receptor (AR) binding agents such as bicalutamide. Although most patients will initially respond to either surgical or medical castration, there is almost always progression to castration-resistant prostate cancer (CRPC) necessitating treatment with more novel agents. [2] However, even drugs such as abiraterone and enzalutamide, two next-generation agents used commonly in metastatic CRPC, have failed to demonstrate persistent efficacy in most patients. [3] ,[4]

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded328    
    Comments [Add]    

Recommend this journal